COMPASS Pathways earnings release, May 13, 2026

COMPASS Pathways plc (CMPS) · Form 8-K, Item 2.02 · Filed · SEC filing

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

• FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data

• CNPV awarded for COMP360 in TRD, further accelerating momentum

• 26-week (Part B) data from COMP006, expected in early Q3 2026

• Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of year

• Successful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028

LONDON & NEW YORK, May 13, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights.

“With regulatory acceleration unfolding, we are working diligently towards our goal of completing the filing of a robust clinical package by Q4 and securing COMP360 approval,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “COMP360 represents a fundamentally different approach for patients with treatment resistant depression, unlike any other treatment approved today. Its transformative clinical profile has the potential to change what patients can expect in terms of both rapid and durable relief, and we are ready to deliver for those who have waited far too long for better options.”

Business Highlights

Accelerated regulatory path

Approval timelines are tracking to Compass’ fastest projected expectations, supported by regulatory acceleration including a rolling New Drug Application (NDA) submission and the Commissioner’s National Priority Review Voucher (CNPV).

• NDA rolling submission underway: o

FDA granted Compass NDA rolling submission and review request, based on strength of positive Phase 3 data. o

Rolling submission and review are underway, with sections of the NDA already submitted. o

26-week (Part B) data from COMP006, expected in early Q3 2026. o

The final NDA submission remains on track for Q4, aligned with the Company’s previously defined accelerated timing.

• Post-NDA filing momentum: o

CNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin for TRD, which has the potential to accelerate filing review time to be completed within 1-2 months. o

White House Executive Order on psychedelics treatments directs the Drug Enforcement Administration (DEA) to initiate and complete review of psychedelic treatment that has successfully completed Phase 3 trials so that rescheduling may proceed as quickly as possible.

Advancing toward commercial launch

• Launch readiness: o

Compass will be launch ready by the end of the year and has assembled a highly experienced commercial leadership team. o

The team is advancing comprehensive launch preparedness efforts, including KOL and HCP education, payer engagement, and ongoing initiatives to support a timely federal and state rescheduling process.

• Delivery infrastructure readiness: o

COMP360 is expected to fit seamlessly across diverse healthcare settings within the current infrastructure of over 7,300 centers¹ offering multi-hour treatments o

Treatment centers are growing rapidly, and existing centers are already scaling in anticipation of a COMP360 launch and additional multi-hour psychedelic treatments coming to market.

COMP360’s transformative clinical profile

• COMP360 has the potential to offer a highly differentiated, transformative clinical profile and is expected to be a blockbuster opportunity.

• COMP360 is the first classic psychedelic² to consistently achieve a highly statistically significant result and clinically meaningful effect in 3 large late-stage trials involving more than 1,000 participants living with TRD, with a generally well-tolerated and safe profile.

• COMP360 demonstrates effects as quickly as within one day after administration with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses.

Financial Highlights

• Research and development expenses were $26.5 million for the three months ended March 31, 2026, compared with $30.9 million during the same period in 2025. The decrease was primarily driven by lower development expenses, reflecting reduced clinical trial costs as our Phase 3 program for COMP360 psilocybin therapy in TRD progresses toward completion, as well reduced discovery program expenses following the termination of certain programs in connection with the reorganization that took place in the fourth quarter of 2024 and the related contract terminations in 2025.

• General and administrative expenses were $16.4 million for the three months ended March 31, 2026, compared with $18.7 million during the same period in 2025. The decrease was primarily due to lower legal and professional fees, driven by higher financing-related costs in 2025, including those associated with warrant issuances, which were expensed as incurred, whereas a greater portion of such costs in 2026 were capitalized. This decrease was partially offset by increased consulting and legal advisory expenses.

• Net income for the three months ended March 31, 2026, was $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted), compared with a net loss of $17.9 million, or $0.20 net loss per share (basic) and $0.24 net loss per share (diluted), during the same period in 2025. The increase in net income was primarily driven by a $130.9 million non-cash gain on fair value adjustment related to our warrants, compared with $19.5 million during the same period in 2025. As the fair value of the warrants fluctuates with our share price, this adjustment can result in significant variability in our reported net income or net loss.

• ... (truncated)ber 31, 2025.

• Debt was $50.5 million as of March 31, 2026, compared with $31.6 million as of December 31, 2025.

Financial Guidance

The current cash position is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

Financial statements

Income Statement

Three Months ended March 31, — (expressed in U.S. Dollars, unless otherwise stated)

Three Months ended March 31, – 2026Three Months ended March 31, – 2025
OPERATING EXPENSES:Research and development26,48030,880
OPERATING EXPENSES:General and administrative16,42418,736
OPERATING EXPENSES:Total operating expenses42,90449,616
OPERATING EXPENSES:Loss from operations:-42,904-49,616
OTHER INCOME (EXPENSE), NET:Fair value change of warrant liabilities130,91619,460
OTHER INCOME (EXPENSE), NET:Benefit from R&D tax credit2,4778,448
OTHER INCOME (EXPENSE), NET:Interest income2,4192,386
OTHER INCOME (EXPENSE), NET:Interest expense-1,465-1,124
OTHER INCOME (EXPENSE), NET:Foreign exchange (losses) gains-7362,133
OTHER INCOME (EXPENSE), NET:Other income484803
OTHER INCOME (EXPENSE), NET:Total other income, net134,09532,106
OTHER INCOME (EXPENSE), NET:Income (loss) before income taxes91,191-17,510
OTHER INCOME (EXPENSE), NET:Income tax benefit (expense)11-354
OTHER INCOME (EXPENSE), NET:Net income (loss)91,202-17,864
OTHER INCOME (EXPENSE), NET:Net income (loss) per share attributable to ordinary shareholders: basic0.71-0.2
OTHER INCOME (EXPENSE), NET:Weighted average ordinary shares outstanding: basic110,064,58189,192,252
OTHER INCOME (EXPENSE), NET:Net loss per share attributable to ordinary shareholders: diluted-0.3-0.24
OTHER INCOME (EXPENSE), NET:Weighted average ordinary shares outstanding: diluted130,266,69398,642
OTHER INCOME (EXPENSE), NET:Net income (loss)91,202-17,864
Other comprehensive income (loss):Foreign exchange translation adjustment-6-117
Other comprehensive income (loss):Comprehensive income (loss)91,196-17,981

Balance Sheet

December 31, — (expressed in U.S. Dollars, unless otherwise stated)

March 31, – 2026December 31, – 2025
CURRENT ASSETS:Cash and cash equivalents466,010149,608
CURRENT ASSETS:Restricted cash379379
CURRENT ASSETS:Prepaid expenses and other current assets44,47841,503
CURRENT ASSETS:Total current assets510,867191,490
NON-CURRENT ASSETS:Operating lease right-of-use assets2,8613,424
NON-CURRENT ASSETS:Deferred tax assets4,0983,751
NON-CURRENT ASSETS:Long-term prepaid expenses and other assets13,91311,684
NON-CURRENT ASSETS:Total assets531,739210,349
CURRENT LIABILITIES:Accounts payable10,87715,222
CURRENT LIABILITIES:Accrued expenses and other liabilities8,9849,214
CURRENT LIABILITIES:Debt, current portion17,523
CURRENT LIABILITIES:Operating lease liabilities - current2,0542,110
CURRENT LIABILITIES:Warrant liabilities131,882203,726
CURRENT LIABILITIES:Total current liabilities153,797247,795
NON-CURRENT LIABILITIES:Debt, non-current portion50,47614,110
NON-CURRENT LIABILITIES:Operating lease liabilities - non-current7791,292
NON-CURRENT LIABILITIES:Total liabilities205,052263,197
SHAREHOLDERS' EQUITY/(DEFICIT):Ordinary shares, £0.008 par value; 134,923,295 and 96,085,785 shares authorized, issued and outstanding at March 31, 2026 and December 31, 2025, respectively1,393973
SHAREHOLDERS' EQUITY/(DEFICIT):Additional paid-in capital1,071,481783,562
SHAREHOLDERS' EQUITY/(DEFICIT):Accumulated other comprehensive loss-14,795-14,789
SHAREHOLDERS' EQUITY/(DEFICIT):Accumulated deficit-731,392-822,594
SHAREHOLDERS' EQUITY/(DEFICIT):Total shareholders' equity/(deficit)326,687-52,848
SHAREHOLDERS' EQUITY/(DEFICIT):Total liabilities and shareholders' equity/(deficit)531,739210,349
Full release

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, statements regarding our expectations regarding our financial guidance; our business strategy and goals; our expectations and projections about the company’s future cash needs and financial results; our expectations regarding the safety or efficacy of our investigational COMP360 psilocybin treatment, including as a treatment of TRD or PTSD; our plans and expectations regarding our clinical trials, including our phase 3 trials in TRD and our phase 2b/3 trial in PTSD; our expectations regarding the time periods for the release of data from Part B of the COMP006 Phase 3 trial for TRD; any implication that past results will be predictive of future results; our expectations regarding the timing of our rolling submission of a new drug application, or NDA, for COMP360 psilocybin treatment in TRD and the timing of the review by the Food and Drug Administration, or FDA, of such NDA, including potential acceleration due to the grant of rolling review and award of a Commissioner’s National Priority Voucher, or CNPV, for COMP360 psilocybin treatment in TRD; the potential for the pivotal phase 3 program in TRD to support regulatory filings and approvals on an accelerated basis or at all; our expectations regarding potential commercial launch timelines and our commercial readiness; our efforts and our ability to obtain regulatory approval and adequate coverage and reimbursement; our ability to transition from a clinical-stage to a commercial-stage organization and effectively launch a commercial product, if regulatory approval is obtained, on an accelerated timeline or at all; and our expectations regarding the benefits of our investigational COMP360 psilocybin treatment, including as a treatment of TRD or PTSD. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Compass’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date; our need for additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our clinical trials; that the rolling review process and/or the Commissioner's National Priority Voucher pilot program may not actually lead to a faster FDA review or approval process; our efforts to obtain FDA approval, or approval from regulatory authorities in other jurisdictions, for our investigational COMP360 psilocybin treatment on an accelerated basis, or at all, may be unsuccessful; our efforts to commercialize and obtain coverage and reimbursement for our investigational COMP360 psilocybin treatment, if approved, may be unsuccessful; the risk that our strategic collaborations will not continue or will not be successful; and our ability to retain key personnel; and those risks and uncertainties described under the heading “Risk Factors” in Compass’s most recent annual report on Form 10-K or quarterly report on Form 10-Q, the prospectus supplement related to the proposed public offering we plan to file and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov... (truncated)ation, future developments or otherwise. These forward-looking statements are based on Compass’s current expectations and speak only as of the date hereof.

References

1.

Data on file

2.

For the definition of classic psychedelic, see Vollenweider, F.X. and Smallridge, J.W., 2022. Classic psychedelic drugs: update on biological mechanisms. Pharmacopsychiatry, 55(03), pp.121-138

Enquiries

Media: Dana Sultan-Rothman, media@compasspathways.com

Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

COMPASS PATHWAYS PLC

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

(expressed in U.S. Dollars, unless otherwise stated)

COMPASS PATHWAYS PLC

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share amounts)

(expressed in U.S. Dollars, unless otherwise stated)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · COMPASS Pathways earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.